Who we are
At Zealand, we are peptide medicine experts.
We have built a world-leading position in the invention, design and development of innovative peptides. Our activities are focused in the growing field of cardio-metabolic diseases, and we have a particularly
strong presence in diabetes, a worldwide pandemic.
The first Zealand invented medicine, Lyxumia® (lixisenatide) for Type 2 diabetes, was launched in 2013, marketed internationally by Sanofi, a global leader in diabetes.
To follow Lyxumia®, we are advancing a broad pipeline of proprietary and partnered assets, including six clinical and several preclinical peptide drug candidates.
Our strategy is to grow the value of our product portfolio and pipeline, building on our R&D peptide capabilities. We retain a diligent approach to risk and apply a partnering model for the commercialization of our products. Our current partners include Sanofi, Helsinn, Boehringer Ingelheim, Eli Lilly and AbbVie.
A dynamic and uniquely skilled team of dedicated people and an agile organisation are some of our key competitive strengths.
We are driven by our ambition and zeal to provide novel peptide medicines and therapeutic solutions that can make a major positive difference in patients’ lives.
This is the Zealand approach to creating revolutionary health solutions.
Other facts and figures
Cash position (end 2013): DKK 311 (EUR 41) million.
2014 financial guidance
Royalties on sales of Lyxumia®;
Expected milestones of DKK 97 (EUR 13) million, of which DKK 82 (EUR 11) million
Net operating expenses of DKK 200-210 (EUR 27-28) million.
Listed on NASDAQ OMX Copenhagen (ZEAL.CO).
Market Cap (per 15 March 2014: DKK 1.7 billion (EUR 226 million).